Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

AYESHA S LALL

Allopathic & Osteopathic Physicians Psychiatry & Neurology Child & Adolescent Psychiatry

NPI
1942221031
CMS profile
389680
Location
GAINESVILLE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$2,751.71

6 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $2,289.37 2
Food and Beverage $462.34 4

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
Boehringer Ingelheim Pharmaceuticals, Inc. $2,751.71 6

Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

AYESHA S LALL

NPI 1942221031 · CMS profile ID 389680

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Child & Adolescent Psychiatry

GAINESVILLE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1942221031?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
AYESHA S LALL, NPI 1942221031, CMS profile ID 389680. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1942221031?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). AYESHA S LALL, NPI 1942221031, CMS profile ID 389680. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1942221031?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
AYESHA S LALL, NPI 1942221031, CMS profile ID 389680, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1942221031?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

6 matching records · $2,751.71 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 6 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–6 of 6.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Boehringer Ingelheim Pharmaceuticals, Inc. $1,100.3302/26/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996928889 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $153.4102/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996928893 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $144.9302/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996928897 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $1,189.0402/26/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996928901 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $82.0002/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996928905 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $82.0002/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997137755 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $197.36 9
PY2020 $21.52 1
PY2021 $95.95 6
PY2022 $791.33 15
PY2023 $2,751.71 6
PY2024 $125.00 1
PY2025 $121.85 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $59,940.10 16
PY2024 Recipient $4,018.01 1
PY2024 Principal investigator $1,034,923.37 95
PY2023 Recipient $433.35 1
PY2023 Principal investigator $392,083.87 69
PY2022 Recipient $300.00 1
PY2022 Principal investigator $934,493.97 37
PY2021 Recipient $50.00 1
PY2021 Principal investigator $735,009.90 45
PY2020 Recipient $1,527.20 10
PY2020 Principal investigator $316,155.93 41
PY2019 Recipient $5,932.16 1
PY2019 Principal investigator $70,452.96 4

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

70 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $1,083.00 12/31/2023 Non-covered Recipient Entity
VERTEX RESEARCH GROUP INC
Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimers Disease No dispute reported 06/30/2026 998413781
Principal investigator 1 ABBVIE INC. $418.50 12/27/2023 Non-covered Recipient Entity
VERTEX CLINICAL RESEARCH LLC
Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimers Disease No dispute reported 06/30/2026 998412831
Principal investigator 1 ABBVIE INC. $14.85 12/26/2023 Non-covered Recipient Entity
VERTEX CLINICAL RESEARCH LLC
Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimers Disease No dispute reported 06/30/2026 998412765
Principal investigator 1 ABBVIE INC. $194.40 12/26/2023 Non-covered Recipient Entity
VERTEX CLINICAL RESEARCH LLC
Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimers Disease No dispute reported 06/30/2026 998412767
Principal investigator 1 ABBVIE INC. $211.16 12/26/2023 Non-covered Recipient Entity
VERTEX CLINICAL RESEARCH LLC
Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimers Disease No dispute reported 06/30/2026 998412771
Principal investigator 1 Eisai Inc. $1,356.30 12/14/2023 Non-covered Recipient Entity
Compass Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1025444343
Principal investigator 1 Janssen Research & Development, LLC $12,286.00 12/08/2023 Non-covered Recipient Entity
Vertex Rsrch Group
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Aticaprant 10 mg and 5 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate to Severe Anhedonia and Inadequate Response to Current Antidepressant Therapy. No dispute reported 06/30/2026 986107259
Principal investigator 1 ABBVIE INC. $10,909.00 12/07/2023 Non-covered Recipient Entity
VERTEX CLINICAL RESEARCH LLC
Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimers Disease No dispute reported 06/30/2026 998410933
Principal investigator 1 ABBVIE INC. $37,845.00 12/04/2023 Non-covered Recipient Entity
VERTEX CLINICAL RESEARCH LLC
Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimers Disease No dispute reported 06/30/2026 998409645
Principal investigator 1 Eisai Inc. $1,186.20 11/22/2023 Non-covered Recipient Entity
Compass Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1039935995
Principal investigator 1 ABBVIE INC. $118.43 11/21/2023 Non-covered Recipient Entity
VERTEX CLINICAL RESEARCH LLC
Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimers Disease No dispute reported 06/30/2026 998408535
Principal investigator 1 ABBVIE INC. $64.80 11/21/2023 Non-covered Recipient Entity
VERTEX CLINICAL RESEARCH LLC
Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimers Disease No dispute reported 06/30/2026 998408537
Principal investigator 1 ABBVIE INC. $28.38 11/21/2023 Non-covered Recipient Entity
VERTEX CLINICAL RESEARCH LLC
Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimers Disease No dispute reported 06/30/2026 998408539
Principal investigator 1 ABBVIE INC. $64.80 11/21/2023 Non-covered Recipient Entity
VERTEX CLINICAL RESEARCH LLC
Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimers Disease No dispute reported 06/30/2026 998408541
Principal investigator 1 ABBVIE INC. $53,902.25 11/07/2023 Non-covered Recipient Entity
VERTEX CLINICAL RESEARCH LLC
Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimers Disease No dispute reported 06/30/2026 998406203
Principal investigator 1 ITI, Inc. $8,000.00 10/20/2023 Non-covered Recipient Entity
VERTEX CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 1042727549
Principal investigator 1 ITI, Inc. $3,000.00 10/20/2023 Non-covered Recipient Entity
VERTEX CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 1042727563
Principal investigator 1 ITI, Inc. $2,529.00 10/20/2023 Non-covered Recipient Entity
VERTEX CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 1042727575
Principal investigator 1 Eisai Inc. $4,703.40 10/19/2023 Non-covered Recipient Entity
Compass Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1039935973
Principal investigator 1 ABBVIE INC. $4,407.75 10/18/2023 Non-covered Recipient Entity
VERTEX CLINICAL RESEARCH LLC
Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimers Disease No dispute reported 06/30/2026 998404501
Principal investigator 1 ACADIA Pharmaceuticals Inc $6,456.60 09/26/2023 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC
ACP-103-047 No dispute reported 06/30/2026 1028879449
Principal investigator 1 Eisai Inc. $14,419.80 09/21/2023 Non-covered Recipient Entity
Compass Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1025444255
Principal investigator 1 ABBVIE INC. $9,323.50 09/07/2023 Non-covered Recipient Entity
VERTEX CLINICAL RESEARCH LLC
Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimers Disease No dispute reported 06/30/2026 998399013
Principal investigator 1 Corium, LLC $10,000.00 08/31/2023 Non-covered Recipient Entity
VERTEX CLINICAL RESEARCH LLC
A Safety/Tolerability and PK Study With Azstarys in Children With ADHD No dispute reported 06/30/2026 987457953
Principal investigator 1 Corium, LLC $7,000.00 08/30/2023 Non-covered Recipient Entity
VERTEX CLINICAL RESEARCH LLC
An Efficacy and Safety Study w/? Azstarys in Children With ADHD No dispute reported 06/30/2026 987457919
Principal investigator 1 Eisai Inc. $11,106.90 08/18/2023 Non-covered Recipient Entity
Compass Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1025444251
Principal investigator 1 ABBVIE INC. $64.80 08/10/2023 Non-covered Recipient Entity
VERTEX CLINICAL RESEARCH LLC
Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimers Disease No dispute reported 06/30/2026 998394659
Principal investigator 1 ABBVIE INC. $28,737.00 08/09/2023 Non-covered Recipient Entity
VERTEX CLINICAL RESEARCH LLC
Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimers Disease No dispute reported 06/30/2026 998393891
Principal investigator 1 Sumitomo Pharma America, Inc. $24.16 08/03/2023 Non-covered Recipient Entity
Vertex Research Group
A 24-Week Open-Label Study Evaluating the Effectiveness Safety and Tolerability of SEP-363856 in Subjects with Schizophrenia Switched from Typical or Atypical Antipsychotic Agents OLE. No dispute reported 06/30/2026 1030280409
Principal investigator 1 Sumitomo Pharma America, Inc. $24.16 08/03/2023 Non-covered Recipient Entity
Vertex Research Group
A 24-Week Open-Label Study Evaluating the Effectiveness Safety and Tolerability of SEP-363856 in Subjects with Schizophrenia Switched from Typical or Atypical Antipsychotic Agents OLE. No dispute reported 06/30/2026 1030280415
Principal investigator 1 Sumitomo Pharma America, Inc. $30.02 08/03/2023 Non-covered Recipient Entity
Vertex Research Group
A 24-Week Open-Label Study Evaluating the Effectiveness Safety and Tolerability of SEP-363856 in Subjects with Schizophrenia Switched from Typical or Atypical Antipsychotic Agents OLE. No dispute reported 06/30/2026 1030280421
Principal investigator 1 Sumitomo Pharma America, Inc. $30.02 08/03/2023 Non-covered Recipient Entity
Vertex Research Group
A 24-Week Open-Label Study Evaluating the Effectiveness Safety and Tolerability of SEP-363856 in Subjects with Schizophrenia Switched from Typical or Atypical Antipsychotic Agents OLE. No dispute reported 06/30/2026 1030280427
Principal investigator 1 Sumitomo Pharma America, Inc. $30.02 08/03/2023 Non-covered Recipient Entity
Vertex Research Group
A 24-Week Open-Label Study Evaluating the Effectiveness Safety and Tolerability of SEP-363856 in Subjects with Schizophrenia Switched from Typical or Atypical Antipsychotic Agents OLE. No dispute reported 06/30/2026 1030280433
Principal investigator 1 Sumitomo Pharma America, Inc. $30.02 08/03/2023 Non-covered Recipient Entity
Vertex Research Group
A 24-Week Open-Label Study Evaluating the Effectiveness Safety and Tolerability of SEP-363856 in Subjects with Schizophrenia Switched from Typical or Atypical Antipsychotic Agents OLE. No dispute reported 06/30/2026 1030280439
Principal investigator 1 Janssen Research & Development, LLC $2,479.00 07/17/2023 Non-covered Recipient Entity
Vertex Rsrch Group
67953964MDD3003 No dispute reported 06/30/2026 986107255
Principal investigator 1 Janssen Research & Development, LLC $9,524.00 07/12/2023 Non-covered Recipient Entity
Vertex Rsrch Group
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Aticaprant 10 mg and 5 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate to Severe Anhedonia and Inadequate Response to Current Antidepressant Therapy. No dispute reported 06/30/2026 986107251
Principal investigator 1 ABBVIE INC. $1,814.75 07/03/2023 Non-covered Recipient Entity
VERTEX CLINICAL RESEARCH LLC
Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimers Disease No dispute reported 06/30/2026 998388909
Principal investigator 1 Janssen Research & Development, LLC $10,000.00 06/21/2023 Non-covered Recipient Entity
Vertex Rsrch Group
67953964MDD3003 No dispute reported 06/30/2026 986107247
Principal investigator 1 Janssen Research & Development, LLC $181.00 06/16/2023 Non-covered Recipient Entity
Vertex Rsrch Group
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Aticaprant 10 mg and 5 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate to Severe Anhedonia and Inadequate Response to Current Antidepressant Therapy. No dispute reported 06/30/2026 986107243
Principal investigator 1 Janssen Research & Development, LLC $13,999.00 06/14/2023 Non-covered Recipient Entity
Vertex Rsrch Group
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Aticaprant 10 mg and 5 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate to Severe Anhedonia and Inadequate Response to Current Antidepressant Therapy. No dispute reported 06/30/2026 986107239
Principal investigator 1 ABBVIE INC. $16,326.70 05/23/2023 Non-covered Recipient Entity
COMPASS RESEARCH LLC
A Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects With Early Alzheimers Disease No dispute reported 06/30/2026 998384217
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $475.52 05/22/2023 Non-covered Recipient Entity
Vertex Research Group
Connex 1 No dispute reported 06/30/2026 1022137935
Principal investigator 1 Eisai Inc. $13,913.10 05/19/2023 Non-covered Recipient Entity
Compass Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1025444235
Principal investigator 1 Janssen Research & Development, LLC $2,934.00 05/17/2023 Non-covered Recipient Entity
Vertex Rsrch Group
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Aticaprant 10 mg and 5 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate to Severe Anhedonia and Inadequate Response to Current Antidepressant Therapy. No dispute reported 06/30/2026 986107233
Principal investigator 1 Janssen Research & Development, LLC $10,000.00 05/10/2023 Non-covered Recipient Entity
Vertex Rsrch Group
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Aticaprant 10 mg and 5 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate to Severe Anhedonia and Inadequate Response to Current Antidepressant Therapy. No dispute reported 06/30/2026 986107229
Principal investigator 1 Sumitomo Pharma America, Inc. $84.60 05/05/2023 Non-covered Recipient Entity
Vertex Research Group
A 24-Week Open-Label Study Evaluating the Effectiveness Safety and Tolerability of SEP-363856 in Subjects with Schizophrenia Switched from Typical or Atypical Antipsychotic Agents OLE. No dispute reported 06/30/2026 1030334003
Principal investigator 1 Sumitomo Pharma America, Inc. $97.60 05/05/2023 Non-covered Recipient Entity
Vertex Research Group
A 24-Week Open-Label Study Evaluating the Effectiveness Safety and Tolerability of SEP-363856 in Subjects with Schizophrenia Switched from Typical or Atypical Antipsychotic Agents OLE. No dispute reported 06/30/2026 1030334009
Principal investigator 1 Sumitomo Pharma America, Inc. $105.30 05/05/2023 Non-covered Recipient Entity
Vertex Research Group
A 24-Week Open-Label Study Evaluating the Effectiveness Safety and Tolerability of SEP-363856 in Subjects with Schizophrenia Switched from Typical or Atypical Antipsychotic Agents OLE. No dispute reported 06/30/2026 1030334015
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $9,500.00 05/04/2023 Non-covered Recipient Entity
Vertex Research Group Inc
Connex 1 No dispute reported 06/30/2026 1022137591
Principal investigator 1 Sumitomo Pharma America, Inc. $6.00 04/07/2023 Non-covered Recipient Entity
Vertex Research Group
A 24-Week Open-Label Study Evaluating the Effectiveness Safety and Tolerability of SEP-363856 in Subjects with Schizophrenia Switched from Typical or Atypical Antipsychotic Agents OLE. No dispute reported 06/30/2026 1030333935
Principal investigator 1 Sumitomo Pharma America, Inc. $15.00 04/07/2023 Non-covered Recipient Entity
Vertex Research Group
A 24-Week Open-Label Study Evaluating the Effectiveness Safety and Tolerability of SEP-363856 in Subjects with Schizophrenia Switched from Typical or Atypical Antipsychotic Agents OLE. No dispute reported 06/30/2026 1030333941
Principal investigator 1 Sumitomo Pharma America, Inc. $21.05 04/07/2023 Non-covered Recipient Entity
Vertex Research Group
A 24-Week Open-Label Study Evaluating the Effectiveness Safety and Tolerability of SEP-363856 in Subjects with Schizophrenia Switched from Typical or Atypical Antipsychotic Agents OLE. No dispute reported 06/30/2026 1030333947
Principal investigator 1 Sumitomo Pharma America, Inc. $28.95 04/07/2023 Non-covered Recipient Entity
Vertex Research Group
A 24-Week Open-Label Study Evaluating the Effectiveness Safety and Tolerability of SEP-363856 in Subjects with Schizophrenia Switched from Typical or Atypical Antipsychotic Agents OLE. No dispute reported 06/30/2026 1030333953
Principal investigator 1 Sumitomo Pharma America, Inc. $36.24 04/07/2023 Non-covered Recipient Entity
Vertex Research Group
A 24-Week Open-Label Study Evaluating the Effectiveness Safety and Tolerability of SEP-363856 in Subjects with Schizophrenia Switched from Typical or Atypical Antipsychotic Agents OLE. No dispute reported 06/30/2026 1030333959
Principal investigator 1 Sumitomo Pharma America, Inc. $36.24 04/07/2023 Non-covered Recipient Entity
Vertex Research Group
A 24-Week Open-Label Study Evaluating the Effectiveness Safety and Tolerability of SEP-363856 in Subjects with Schizophrenia Switched from Typical or Atypical Antipsychotic Agents OLE. No dispute reported 06/30/2026 1030333967
Principal investigator 1 Sumitomo Pharma America, Inc. $45.03 04/07/2023 Non-covered Recipient Entity
Vertex Research Group
A 24-Week Open-Label Study Evaluating the Effectiveness Safety and Tolerability of SEP-363856 in Subjects with Schizophrenia Switched from Typical or Atypical Antipsychotic Agents OLE. No dispute reported 06/30/2026 1030333973
Principal investigator 1 Sumitomo Pharma America, Inc. $45.03 04/07/2023 Non-covered Recipient Entity
Vertex Research Group
A 24-Week Open-Label Study Evaluating the Effectiveness Safety and Tolerability of SEP-363856 in Subjects with Schizophrenia Switched from Typical or Atypical Antipsychotic Agents OLE. No dispute reported 06/30/2026 1030333979
Principal investigator 1 Sumitomo Pharma America, Inc. $45.03 04/07/2023 Non-covered Recipient Entity
Vertex Research Group
A 24-Week Open-Label Study Evaluating the Effectiveness Safety and Tolerability of SEP-363856 in Subjects with Schizophrenia Switched from Typical or Atypical Antipsychotic Agents OLE. No dispute reported 06/30/2026 1030333985
Principal investigator 1 Sumitomo Pharma America, Inc. $45.03 04/07/2023 Non-covered Recipient Entity
Vertex Research Group
A 24-Week Open-Label Study Evaluating the Effectiveness Safety and Tolerability of SEP-363856 in Subjects with Schizophrenia Switched from Typical or Atypical Antipsychotic Agents OLE. No dispute reported 06/30/2026 1030333989
Principal investigator 1 Sumitomo Pharma America, Inc. $49.50 04/07/2023 Non-covered Recipient Entity
Vertex Research Group
A 24-Week Open-Label Study Evaluating the Effectiveness Safety and Tolerability of SEP-363856 in Subjects with Schizophrenia Switched from Typical or Atypical Antipsychotic Agents OLE. No dispute reported 06/30/2026 1030333997
Principal investigator 1 Eisai Inc. $7,656.30 04/05/2023 Non-covered Recipient Entity
Compass Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1025444227
Principal investigator 1 ACADIA Pharmaceuticals Inc $20,622.12 03/22/2023 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC
ACP-103-046 No dispute reported 06/30/2026 1028876461
Principal investigator 1 ACADIA Pharmaceuticals Inc $2,750.00 03/22/2023 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC
ACP-103-046 No dispute reported 06/30/2026 1028876475
Principal investigator 1 Eisai Inc. $1,129.50 02/20/2023 Non-covered Recipient Entity
Compass Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1025444223
Principal investigator 1 ABBVIE INC. $9,500.00 02/02/2023 Non-covered Recipient Entity
VERTEX RESEARCH GROUP INC
Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimers Disease No dispute reported 06/30/2026 998368081
Recipient Eli Lilly and Company $433.35 01/23/2023 Covered Recipient Physician A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2) No dispute reported 06/30/2026 1038047935
Principal investigator 1 Eisai Inc. $4,574.70 01/20/2023 Non-covered Recipient Entity
Compass Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1025444219
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $5,750.00 01/19/2023 Non-covered Recipient Entity
VERTEX RESEARCH GROUP INC
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN MIGRAINE PREVENTION IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1046319195
Principal investigator 1 Eisai Inc. $16,920.00 01/06/2023 Non-covered Recipient Entity
Compass Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1025444215
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $1,773.36 01/01/2023 Non-covered Recipient Entity
Vertex Research Group
Connex 1 No dispute reported 06/30/2026 1022011721